Medpace is a midsize, clinical contract research organization based in Cincinnati, Ohio. it provides services for Phase I-IV of drug and medical device development services including regulatory services and central laboratory services. The company started trading stock as a public firm in 2016.
History
Dr. August Troendle founded Medpace in Cincinnati, Ohio in 1992 as Medical Rearch Services. Dr. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol. With a team of industry physicians, Dr. Jonathan Issacsohn and Dr. Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, Dr. David Orloff is regarded as an industry opinion leader in the study of metabolic diseases - most specifically diabetes and obesity. Dr. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce. Medpace completed construction on a new campus in 2012 in Madisonville, a village in the city of Cincinnati. This was a project completed in cooperation with Madisonville, the City of CincinnatiDepartment of Economic Development, and the State of Ohio. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the artLEED certified campus.
2010-Medpace acquires Medical Consulting Dr. Schlichtiger, GmbH, in Germany
2012-Medpace acquires MediTech BV, a medical device consultancy in the Netherlands.
Ownership
In 2011, CCMP Capital acquired 80% of the firm for. Three years later, in February 2014, CCMP auctioned their 80% stake in the firm, the winner of which was Cinven, who paid. Two and a half years after Cinven's purchase, Medpace closed its initial public offering on August 16, 2016 after selling 8,050,000 shares of common stock, becoming a public, shareholder-owned concern.
Recognition
In May 2009, Medpace was recognized by CenterWatch, a CRO industry publication as a top CRO by investigative sites. In 2011 and 2012 Medpace was given the Eagle Award, an industry award by investigative sites for criteria including professionalism, partnership, efficiencies and financial considerations
